Navigation Links
Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Date:8/28/2008

kaline phosphatase (ALP) ranging from no effect in the lowest dose group to a marked reduction in the higher dose groups. ALP is a severity marker of bony metastatic disease and of prognostic importance.

The study has also further confirmed the safety of Alpharadin and shown its benign side-effect profile. In fact, the higher the dose of Alpharadin that patients received, the fewer adverse events were experienced. This reproduces the safety profile of the earlier BC1-02 Phase II study where the Alpharadin group experienced fewer adverse effects than the placebo comparator group. Importantly for a drug in this clinical setting no significant bone marrow toxicity was observed in patients receiving Alpharadin.

The full results of the BC1-03 study will be submitted for publication in a peer-reviewed journal.

The principal investigator of the study Professor Sten Nilsson at the Karolinska Hospital in Stockholm said: "These results showing the beneficial impact of Alpharadin in terms of pain palliation are important, as improved quality of life, alongside increased survival, are the two key goals of anti-cancer therapy of patients with skeletal metastases."

Commenting on today's further positive news with Alpharadin, Algeta's President and CEO, Dr. Thomas Ramdahl, said: "These results build on the positive Phase II clinical data package that we have already assembled with Alpharadin, the highlight of which was the significant survival benefits that we have already reported in patients with HRPC.

Based on our clinical trials to-date I am very confident that Alpharadin has the potential to become an important new therapy for patients with prostate cancer. This view has been reinforced by the enthusiastic and positive response we have received from key opinion leaders around the world to our unique approach to treating HRPC."

Algeta has recently started enrolling patients for the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic
'/>"/>

SOURCE Algeta
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
2. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
3. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
4. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
5. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
8. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
9. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
10. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
11. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  AMRI (NASDAQ: ... announced a strategic collaboration focused on the development, ... active pharmaceutical ingredients, ("APIs"). The collaboration combines Saneca,s ... their expertise in developing and manufacturing controlled substance ... to tech transfer processes into these facilities. The ...
(Date:8/31/2015)... August 31, 2015 Premune ... into an exclusive licensing agreement for Redonyl ® ... $300 million USD veterinary dermatology market, is a nutritional ... support healthy skin in dogs and cats. Redonyl ® ... , and has been received positively in the ...
(Date:8/31/2015)... Aug. 31, 2015  QT Vascular Ltd., together with its ... with its subsidiaries, the "Group"), a global company ... advanced therapeutic solutions for the minimally invasive treatment ... of the below-the-knee ("BTK") cohort of patients in ... presented on August 15, 2015 at the 5th ...
Breaking Medicine Technology:AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4Premune Broadens Portfolio With Novel Innovet Skin Health Product 2Premune Broadens Portfolio With Novel Innovet Skin Health Product 3Premune Broadens Portfolio With Novel Innovet Skin Health Product 4Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4
... , April 29, 2010 Albireo today,announced ... recent study,assessing the safety, tolerability and efficacy of A3309 ... compound for,the treatment of irritable bowel syndrome with constipation ... during the 2010,Digestive Disease Week (DDW) annual meeting being ...
... SALT LAKE CITY , April 28 Sonic Innovations, ... Administration (VA), is conducting ongoing training events for government clinicians.  The company ... in San Diego, California and April 25 through ... for May 3 through 5 in Salt Lake City, ...
Cached Medicine Technology:Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 2Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 3Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 4Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation 5Sonic Innovations Conducts National Training Events for Government Clinicians 2Sonic Innovations Conducts National Training Events for Government Clinicians 3
(Date:9/1/2015)... ... September 01, 2015 , ... MAP ... the Premier Outcomes-Driven Provider Network. It is the first-ever, standardized, outcomes-driven network ... provision of quality addiction treatment and the utilization of resources to track ...
(Date:9/1/2015)... Pasadena, California (PRWEB) , ... September 01, 2015 ... ... Anna Arrowsmith interviewed dating men and pick-up artists about their experiences of female ... alongside men’s bodily concerns, including penis issues, as well as their relationships with ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Routines… every family ... routines can help make things easier for parents, caregivers and children too. Here are ... transitions both big and small become more fluid. When a routine is implemented into ...
(Date:9/1/2015)... ... 2015 , ... September is Baby Safety Month, and Lightning Labels ... keep little ones' safety top of mind at all times. , Sponsored by the ... to the JPMA's Baby Safety Zone website, this year's theme is A Room with ...
(Date:9/1/2015)... ... September 01, 2015 , ... Curly ... professional hair salons. This highly anticipated partnership between Curly Hair Solutions™ and Trade ... Collection. Founder Jonathan Torch and the Curly Hair Solutions™ team could not be ...
Breaking Medicine News(10 mins):Health News:MAP Health Management Launches the MAP Recovery Network 2Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:Back into the Swing of Things: How Family Routines Benefit Children 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:Curly Hair Solutions™ Partners With Trade Secrets 2
... As part of its ongoing commitment to keeping ... recognized leader in innovative healthcare administration for over 20 ... new full-service pharmacy benefit management (PBM) program, MagnaCareRx. ... pharmacy benefit management. With costs rising, plan sponsors can,t ...
... findings , TUESDAY, July 7 (HealthDay News) -- Parents ... that show a reduced-dose schedule for the pneumococcal vaccine ... The current recommended dose schedule for 7-valent pneumococcal conjugate ... age of 6 months, followed by a booster vaccination ...
... linked in studies to lower incidence of type 2 diabetes ... of a protein created by fat cells are associated with ... protein, adiponectin, appears to have anti-inflammatory and insulin-sensitizing capabilities, according ... the Journal of the American Medical Association . , ...
... Ulrich Stroeher, Chairman of the Advisory,Board of Berlin Heart, today ... the company on 30 September 2009. , ... one of the,intellectual fathers of the successful ventricular assist device ... this area as,coordinator for projects with external cooperation partners. He ...
... , ATLANTA, July 7 Crawford Canada,s Bill Johnstone ... Company,s (NYSE: CRDA ; CRDB) Global Technical ... designed to more effectively coordinate and grow this market-leading ... is a major differentiator for Crawford worldwide in the ...
... ... ... roving weather star, Al Roker, has packed up his Penske truck once again to hit ... consecutive year, "Lend a Hand" continues its mission to help small charities across the country ...
Cached Medicine News:Health News:MagnaCare Answers Need for New Prescription Drug Program 2Health News:Fewer Shots Could Still Protect Kids From Pneumonia 2Health News:Fat-Cell Protein May Reduce Diabetes Risk 2Health News:Fat-Cell Protein May Reduce Diabetes Risk 3Health News:Berlin Heart Announces Restructuring of Management 2Health News:Bill Johnstone Named Senior Vice President of Crawford's Global Technical Services for the Americas 2Health News:Supergoop! Award-Winning SPF 30 Sunscreen & Skin Protection Lotion Featured On The Today Show 2
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
Hemagglutination slide test for the differential qualitative detection and quantitative determination of infectious mononucleosis and other heterophile antibodies in serum or plasma....
Color-enhanced hemagglutination slide test for the rapid qualitative and semi-quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
... Inverness Medical Professional Diagnostics is a leading ... IFA and DFA test menu that includes ... STDs as well as miscellaneous conjugates and ... you a wide assortment of substrates and ...
Medicine Products: